Notice Type
Departmental
Consent to the Distribution of New Medicines Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Oxybutynin chloride 5 mg Tablet Apotex Inc., Weston, Ontario, Canada Apo-Oxybutynin Irbesartan 75 mg, 150 mg, 300 mg Tablets Bristol-Myers Squibb Company, Evansville, Indiana, United States of America and Sanofi Winthrop Industrie, Ambares, France Avapro Stannous fluoride 0.4% w/w Gel, oral Colgate Oral Pharmaceuticals, Dallas, Texas, United States of America Colgate Gel-Kam Stannous Fluoride, Fluoride Treatment Gel-Fresh Mint Oestradiol 2 mg (25 g/24 hours), 4 mg (50 g/24 hours), 8 mg (100 g/24 hours) Transdermal patch Lohmann Therapie-Systeme GmbH & Co, Neuwied, Germany Dermestril Isosorbide mononitrate 60 mg Tablet, modified release Pacific Pharmaceuticals Limited, Mount Wellington, Auckland Duride White tablet: Oestradiol 1.5 mg Yellow tablet: Desogestrel 0.15 mg, oestradiol 1.5 mg Tablets Organon International BV., Oss, The Netherlands Liseta Dextromethorphan hydrobromide 3 mg/mL, guaiphenesin 20 mg/mL Solution, oral Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia Robitussin DM Aspirin 300 mg Tablet Sigma Pharmaceuticals Pty Limited, Croydon, Victoria, Australia Soluble Aspirin Dated this 6th day of April 1998. G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.
Publication Date
9 Apr 1998

Notice Number

1998-go2437

Page Number

1166